← Leaderboards
Kenneth Schultz
Trethera Corporation
$10,767,220
Attributed
$10,767,220
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.1M · FY2022–25$10M$7.5M$5M$2.5M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$10,767,220 · 10
By mechanism
R44$6,647,853 · 5
R42$2,511,791 · 2
R41$1,607,576 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Small Molecule Inhibitor”
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$6,931,223
- George Gaitanaris · Omeros Corporation$6,689,019
- James M Balkovec · Hackensack University Medical Center$5,504,094
- Alexander Federation · Talus Bioscience, Inc.$4,432,425
- William A. Erhardt · Oligomerix, Inc$4,294,362
- Julian A Symons · Hackensack University Medical Center$4,228,031
Research focus
Small Molecule InhibitorSide EffectDosePathway InteractionsDeoxycytidine KinaseEnzymesPositron-Emission TomographyDeoxyribonucleosidesPharmaceutical PreparationsDna BiosynthesisSmall MoleculeSuccessDrug TargetingIn VivoNucleoside InhibitorPlasmaImmune SystemSolid NeoplasmResponseRadiotracerDeoxycytidineImmunePhase I Clinical TrialsNovel Therapeutics
Grant awards (16)
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors$1,150,000
R44 · FY2025 · CA · contact PI
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)$1,000,000
R44 · FY2025 · AI · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$994,978
R44 · FY2025 · AI · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease$905,290
R42 · FY2025 · DK · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis$622,448
R42 · FY2025 · EY · contact PI
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer$406,500
R44 · FY2025 · CA · contact PI
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)$1,050,000
R44 · FY2024 · AI · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types$696,570
R44 · FY2024 · CA · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis$615,858
R42 · FY2024 · EY · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$305,715
R41 · FY2024 · AI · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)$297,146
R41 · FY2024 · AI · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types$1,349,805
R44 · FY2023 · CA · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease$395,119
R41 · FY2023 · DK · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$305,135
R41 · FY2023 · AI · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)$304,461
R41 · FY2023 · AI · contact PI
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis$368,195
R42 · FY2022 · EY · contact PI